Education
About Us
Working with TipRanks
Follow Us
Kymera Therapeutics (KYMR)
NASDAQ:KYMR
KYMR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$19.45 - $59.00
Previous CloseN/A
Volume48.51K
Average Volume (3M)834.16K
Market Cap
$4.02B
Enterprise Value$2.93B
Total Cash (Recent Filing)$665.45M
Total Debt (Recent Filing)$85.71M
Price to Earnings (P/E)―
Beta2.48
Next Earnings
Oct 30, 2025EPS Estimate
-0.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.95
Shares Outstanding71,497,600
10 Day Avg. Volume809,288
30 Day Avg. Volume834,156
Financial Highlights & Ratios
PEG Ratio-0.74
Price to Book (P/B)3.61
Price to Sales (P/S)64.14
P/FCF Ratio-14.56
Enterprise Value/Market Cap0.73
Enterprise Value/Revenue65.56
Enterprise Value/Gross Profit68.76
Enterprise Value/Ebitda-10.58
Forecast
1Y Price Target
$64.33Price Target Upside12.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
Bulls Say, Bears Say
Bulls Say
Program DevelopmentThe recent completion of enrollment for the program is seen as a positive step towards the atopic dermatitis readout.
Safety And EfficacyKymera presented comprehensive data showing rapid, deep, and durable STAT6 knockdown with a clean safety profile, supporting the potential efficacy of KT-621.
Treatment EfficacyKymera is confident in achieving significant reductions in TARC, EASI, and NRS pruritus, which are key indicators of treatment efficacy.
Bears Say
Clinical OutcomesThe robust Th2 biomarker suppression in BroADen may not necessarily translate into clinically meaningful EASI 75 and pruritus NRS improvements on Day 28.
Investor ConcernsThe rationale for the second dose in the Ph 1b is driving some investor confusion.
Kymera Therapeutics News
KYMR FAQ
What was Kymera Therapeutics’s price range in the past 12 months?
Kymera Therapeutics lowest stock price was $19.45 and its highest was $59.00 in the past 12 months.
What is Kymera Therapeutics’s market cap?
Kymera Therapeutics’s market cap is $4.02B.
When is Kymera Therapeutics’s upcoming earnings report date?
Kymera Therapeutics’s upcoming earnings report date is Oct 30, 2025 which is in 18 days.
How were Kymera Therapeutics’s earnings last quarter?
Kymera Therapeutics released its earnings results on Aug 11, 2025. The company reported -$0.95 earnings per share for the quarter, missing the consensus estimate of -$0.81 by -$0.14.
Is Kymera Therapeutics overvalued?
According to Wall Street analysts Kymera Therapeutics’s price is currently Undervalued.
Does Kymera Therapeutics pay dividends?
Kymera Therapeutics does not currently pay dividends.
What is Kymera Therapeutics’s EPS estimate?
Kymera Therapeutics’s EPS estimate is -0.76.
How many shares outstanding does Kymera Therapeutics have?
Kymera Therapeutics has 71,497,600 shares outstanding.
What happened to Kymera Therapeutics’s price movement after its last earnings report?
Kymera Therapeutics reported an EPS of -$0.95 in its last earnings report, missing expectations of -$0.81. Following the earnings report the stock price went down -7.238%.
Which hedge fund is a major shareholder of Kymera Therapeutics?
Currently, no hedge funds are holding shares in KYMR
Kymera Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$64.33 (12.45% Upside)
$64.33 (12.45% Upside)
Blogger Sentiment
Bullish
KYMR Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 708.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.0%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
31.56%
12-Months-Change
Fundamentals
Return on Equity
-33.26%
Trailing 12-Months
Asset Growth
36.93%
Trailing 12-Months
Company Description
Kymera Therapeutics
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
KYMR Company Deck
KYMR Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant advancements in Kymera's clinical programs and strategic collaborations, bolstering its financial position and setting the stage for future growth. Despite some uncertainties in dose selection and program transitions, the positive momentum and strong financial backing indicate a promising outlook.View all KYMR earnings summariesKYMR Stock 12 Month Forecast
Average Price Target
$64.33
▲(12.45% Upside)
Technical Analysis
Protagonist Therapeutics
―
Apellis Pharmaceuticals
―
Crinetics Pharmaceuticals
―
Akero Therapeutics
―
MoonLake Immunotherapeutics
―
Ownership Overview
11.97% Insiders
29.59% Mutual Funds
0.72% Other Institutional Investors
45.16% Public Companies and
Individual Investors